 |
|
 |
Cefaseptin Palatable Tablets |
|
Presentation Film coated tablets available in two strengths. Cefaseptin 120mg Tablets contain Cefalexin 120 mg (as Cefalexin Monohydrate) and Titanium Dioxide (E171) 1.246mg per tablet as colouring agent. Cefaseptin 600mg Tablets contain Cefalexin 600 mg (as Cefalexin Monohydrate) and Titanium Dioxide (E171) 6.23mg per tablet as colouring agent. Uses Canine pyoderma caused by Staphylococcus intermedius
|
|
Presentation
Film coated tablets available in two strengths.
Cefaseptin 120mg Tablets contain Cefalexin 120 mg (as Cefalexin Monohydrate) and Titanium Dioxide (E171) 1.246mg per tablet as colouring agent.
Cefaseptin 600mg Tablets contain Cefalexin 600 mg (as Cefalexin Monohydrate) and Titanium Dioxide (E171) 6.23mg per tablet as colouring agent.
Uses
Canine pyoderma caused by Staphylococcus intermedius
|
|
Dosage and administration
25 mg/kg body weight orally, twice daily for up to 3 weeks. The treatment should be re-assessed if no improvement is seen after 14 days.
120MG TABLETS
600MG TABLETS
5kg bodyweight
1 tablet twice daily
-
10kg bodyweight
2 tablets twice daily
-
12kg bodyweight
-
½ tablet twice daily
24 kg bodyweight
-
1 tablet twice daily
|
|
Contra-indications, warnings, etc
Do not use in animals with known hypersensitivity to cefalexin or penicillin
Special precautions for use in animals
Where renal insufficiency exists, the dose rate should be reduced. Where serious disturbances of the gastrointestinal tract occur, treatment should be discontinued.
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.
Adverse reactions (frequency and seriousness)
Mild diarrhoea, salivation and vomiting may occur in rare cases.
Renal insufficiency requires a reduced dose rate as this condition influences plasma levels and overall distribution
Cefalexin may cause sensitisation (allergy)
Use during pregnancy and lactation
No evidence of adverse effects (teratogenic or otherwise) have been seen in pregnant bitches or queens. The product should only be used where the clinical benefits outweigh the potential risks.
Interaction with other medicinal products and other forms of interaction
Cross sensitisation and cross-resistance may exist between penicillins and cephalosporins.
Overdose
There is no specific information relating to overdosage. The recommended posology should be followed.
Withdrawal period
Not applicable.
Operator warnings
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
1.Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
2.Handle this product with great care to avoid exposure, taking all recommended precautions.
3.If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning.
Swellings of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.
4.Wash hands after use.
Pharmaceutical precautions
Do not store above 25°C.
Store in a dry place.
Protect from light.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with national requirements.
|
|
 |